Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design

Drug Metabolism and Disposition

Volumn 43, Issue 4, 2015, Pages 490-509

  Lee, Caroline A ^f   O'connor, Meeghan A ^a   Ritchie, Tasha K ^e   Galetin, Aleksandra ^b   Cook, Jack A ^c   Ragueneau Majlessi, Isabelle ^d   Ellens, Harma ^f   Feng, Bo ^c   Taub, Mitchell E ^a   Paine, Mary F ^g   Polli, Joseph W ^e   Ware, Joseph A ^h   Zamek Gliszczynski, Maciej J ^e  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c PFIZER INC   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e GLAXOSMITHKLINE   (United States)

^f Drug Metabolism and Pharmacokinetics GlaxoSmithKline ^*  (United States)

^g WASHINGTON STATE UNIVERSITY   (United States)

^h GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CURCUMIN; ELACRIDAR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAPATINIB; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1; PROTEIN TYROSINE KINASE INHIBITOR; PROTON PUMP INHIBITOR; ROSUVASTATIN; SALAZOSULFAPYRIDINE; TOPOTECAN; UNCLASSIFIED DRUG; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; DRUG; TUMOR PROTEIN;

CROHN DISEASE; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DISPOSITION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GENETIC TRANSFECTION; GENOTYPE; HUMAN; IC50; NONHUMAN; OVARY CARCINOMA; PHARMACODYNAMICS; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SMALL CELL LUNG CANCER; STUDY DESIGN; ULCERATIVE COLITIS; ADVERSE DRUG REACTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG INTERACTION; ENZYME SPECIFICITY; GENETICS; METABOLISM; METHODOLOGY; MULTIDRUG RESISTANCE; PHARMACOKINETICS; PRACTICE GUIDELINE;

ATP-BINDING CASSETTE TRANSPORTERS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; NEOPLASM PROTEINS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRACTICE GUIDELINES AS TOPIC; RESEARCH DESIGN; SUBSTRATE SPECIFICITY;

EID: 84940475931     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.062174     Document Type: Review

References (216)

1. Abodunde OA, LevakaVeera RR, Desai R, Nweke N, and Berrou M (2013) Colchicine toxicity precipitated by interaction with sunitinib. J Clin Pharm Ther 38:243-245.
2. Adkison KK, Vaidya SS, Lee DY, Koo SH, Li L, Mehta AA, Gross AS, Polli JW, Humphreys JE, and Lou Y, et al. (2010) Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. J Pharm Sci 99: 1046-1062.
3. Adkison KK, Vaidya SS, Lee DY, Koo SH, Li L, Mehta AA, Gross AS, Polli JW, Lou Y, and Lee EJ (2008) The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects. Br J Clin Pharmacol 66:233-239.
4. Agarwal S, Mittapalli RK, Zellmer DM, Gallardo JL, Donelson R, Seiler C, Decker SA, Santacruz KS, Pokorny JL, and Sarkaria JN, et al. (2012) Active efflux of dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents. Mol Cancer Ther 11:2183-2192.
5. Ahmed-Belkacem A, Pozza A, Muñoz-Martínez F, Bates SE, Castanys S, Gamarro F, Di Pietro A, and Pérez-Victoria JM (2005) Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res 65:4852-4860.
6. Ai L, Zhu L, Yang L, Ge G, Cao Y, Liu Y, Fang Z, and Zhang Y (2014) Selectivity for inhibition of nilotinib on the catalytic activity of human UDP-glucuronosyltransferases. Xenobiotica 44: 320-325.
7. Allred AJ, Bowen CJ, Park JW, Peng B, Williams DD, Wire MB, and Lee E (2011) Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers. Br J Clin Pharmacol 72: 321-329.
8. Ando T, Kusuhara H, Merino G, Alvarez AI, Schinkel AH, and Sugiyama Y (2007) Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Drug Metab Dispos 35:1873-1879.
9. Appiah-Opong R, Commandeur JN, van-Vugt-Lussenburg B, and Vermeulen NP (2007) Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products. Toxicology 235:83-91.
10. Beéry E, Rajnai Z, Abonyi T, Makai I, Bánsághi S, Erdo F, Sziráki I, Herédi-Szabó K, Kis E, and Jani M, et al. (2012) ABCG2 modulates chlorothiazide permeability-in vitrocharacterization of its interactions. Drug Metab Pharmacokinet 27:349-353.
11. Bence AK, Anderson EB, Halepota MA, Doukas MA, DeSimone PA, Davis GA, Smith DA, Koch KM, Stead AG, and Mangum S, et al. (2005) Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs 23:39-49.
12. Bhullar J, Natarajan K, Shukla S, Mathias TJ, Sadowska M, Ambudkar SV, and Baer MR (2013) The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions. PLoS One 8: e71266.
13. Bliesath H, Huber R, Steinijans VW, Koch HJ, Kunz K, and Wurst W (1996a) Pantoprazole does not interact with nifedipine in man under steady-state conditions. Int J Clin Pharmacol Ther 34:51-55.
14. Bliesath H, Huber R, Steinijans VW, Koch HJ, Kunz K, and Wurst W (1996b) Pantoprazole does not interact with nifedipine in man under steady-state conditions. Int J Clin Pharmacol Ther 34 (1 Suppl):S81-S85.
15. Bliesath H, Huber R, Steinijans VW, Koch HJ, Wurst W, and Mascher H (1996c) Lack of pharmacokinetic interaction between pantoprazole and diclofenac. Int J Clin Pharmacol Ther 34 (1 Suppl):S76-S80.
16. Bliesath H, Huber R, Steinijans VW, Koch HJ, Wurst W, and Mascher H (1996d) Lack of pharmacokinetic interaction between pantoprazole and diclofenac. Int J Clin Pharmacol Ther 34:152-156.
17. Bullock KE, Petros WP, Younis I, Uronis HE, Morse MA, Blobe GC, Zafar SY, Gockerman JP, Lager JJ, and Truax R, et al. (2011) A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). Cancer Chemother Pharmacol 67: 465-474.
18. Busti AJ, Bain AM, Hall RG 2nd, Bedimo RG, Leff RD, Meek C, and Mehvar R (2008) Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol 51:605-610.
19. Castellino S, O'Mara M, Koch K, Borts DJ, Bowers GD, and MacLauchlin C (2012) Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity. Drug Metab Dispos 40:139-150.
20. Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, and Kruh GD (2003) Transport of methotrexate, methotrexate polyglutamates, and 17betaestradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 63:4048-4054.
21. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, and Ming- Shiang W, et al. (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21 (4B):2895-2900.
22. Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, and Koch KM, et al. (2014) Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol 32:1472-1479.
23. Choi MK and Song IS (2012) Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil. J Pharm Pharmacol 64:1074-1083.
24. Chu X, Cai X, Cui D, Tang C, Ghosal A, Chan G, Green MD, Kuo Y, Liang Y, and Maciolek CM, et al. (2013a) In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug Metab Dispos 41:668-681.
25. Chu X, Korzekwa K, Elsby R, Fenner K, Galetin A, Lai Y, Matsson P, Moss A, Nagar S, and Rosania GR, et al.; International Transporter Consortium (2013b) Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. Clin Pharmacol Ther 94:126-141.
26. Crowe A and Wright C (2012) The impact of P-glycoprotein mediated efflux on absorption of 11 sedating and less-sedating antihistamines using Caco-2 monolayers. Xenobiotica 42: 538-549.
27. Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, and Sparreboom A, et al. (2006) Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 98:1739-1742.
28. Custodio JM, Wang H, Hao J, Lepist EI, Ray AS, Andrews J, Ling KH, Cheng A, Kearney BP, and Ramanathan S (2014) Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin. J Clin Pharmacol 54:649-656.
29. Dahan A and Amidon GL (2009) Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol 297:G371-G377.
30. De-Jong FA, Marsh S, Mathijssen RH, King C, Verweij J, Sparreboom A, and McLeod HL (2004) ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 10:5889-5894.
31. Dickens D, Owen A, Alfirevic A, and Pirmohamed M (2013) ABCB1 single nucleotide polymorphisms (1236C.T, 2677G.T, and 3435C.T) do not affect transport activity of human P-glycoprotein. Pharmacogenet Genomics 23:314-323.
32. Dong PP, Fang ZZ, Zhang YY, Ge GB, Mao YX, Zhu LL, Qu YQ, Li W, Wang LM, and Liu CX, et al. (2011) Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib. Acta Pharmacol Sin 32:399-407.
33. Duursema L, Müller FO, Schall R, Middle MV, Hundt HK, Groenewoud G, Steinijans VW, and Bliesath H (1995) Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol 39:700-703.
34. Egan A and Colman E (2011) Weighing the benefits of high-dose simvastatin against the risk of myopathy. N Engl J Med 365:285-287.
35. Elsby R, Hilgendorf C, and Fenner K (2012) Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1. Clin Pharmacol Ther 92:584-598.
36. Elsby R, Smith V, Fox L, Stresser D, Butters C, Sharma P, and Surry DD (2011) Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions. Xenobiotica 41:764-783.
37. Endres CJ, Hsiao P, Chung FS, and Unadkat JD (2006) The role of transporters in drug interactions. Eur J Pharm Sci 27:501-517.
38. Englund G, Lundquist P, Skogastierna C, Johansson J, Hoogstraate J, Afzelius L, Andersson TB, and Projean D (2014) Cytochrome p450 inhibitory properties of common efflux transporter inhibitors. Drug Metab Dispos 42:441-447.
39. Englund G, Rorsman F, Rönnblom A, Karlbom U, Lazorova L, Gråsjö J, Kindmark A, and Artursson P (2006) Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci 29:269-277.
40. Enokizono J, Kusuhara H, and Sugiyama Y (2007a) Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect. Drug Metab Dispos 35:209-214.
41. Enokizono J, Kusuhara H, and Sugiyama Y (2007b) Regional expression and activity of breast cancer resistance protein (Bcrp/Abcg2) in mouse intestine: overlapping distribution with sulfotransferases. Drug Metab Dispos 35:922-928.
42. European Medicines Agency (2013) Guideline on the Investigation of Drug Interactions. European Medicines Agency, London, UK. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/07/WC500129606.pdf.
43. Farrell TL, Poquet L, Dew TP, Barber S, and Williamson G (2012) Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study. Drug Metab Dispos 40:397-406.
44. Ferrante E, Grasso S, Corbo GM, and Ciappi G (1991) [The measurement of bronchial hyperreactivity for military service fitness]. Recenti Prog Med 82:520-522.
45. Fujita Y, Noguchi K, Suzuki T, Katayama K, and Sugimoto Y (2013) Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein. BMC Res Notes 6:445.
46. Furukawa T, Wakabayashi K, Tamura A, Nakagawa H, Morishima Y, Osawa Y, and Ishikawa T (2009) Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations. Pharm Res 26:469-479.
47. Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, and Gescher AJ (2005) Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14:120-125.
48. Giacomini KM, Balimane PV, Cho SK, Eadon M, Edeki T, Hillgren KM, Huang SM, Sugiyama Y, Weitz D, and Wen Y, et al.; International Transporter Consortium (2013) International Transporter Consortium commentary on clinically important transporter polymorphisms. Clin Pharmacol Ther 94:23-26.
49. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
50. Gong IY, Mansell SE, and Kim RB (2013) Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry. Basic Clin Pharmacol Toxicol 112:164-170.
51. Goodman LS, Gilman A, Brunton LL, Lazo JS, and Parker KL (2005) Goodman & Gilman's the Pharmacological Basis of Therapeutics, McGraw-Hill, New York.
52. Goodman LS, Hardman JG, Limbird LE, and Gilman AG (2001) Goodman & Gilman's the Pharmacological Basis of Therapeutics, McGraw-Hill, New York.
53. Gugler R, Hartmann M, Rudi J, Brod I, Huber R, Steinijans VW, Bliesath H, Wurst W, and Klotz U (1996) Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. Br J Clin Pharmacol 42:249-252.
54. Haagsma CJ, Russel FG, Vree TB, Van Riel PL, and Van de Putte LB (1996) Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. Br J Clin Pharmacol 42:195-200.
55. Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, Lee JE, Lee DH, Kim HT, and Lee JS (2007) Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecanpharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110:138-147.
56. Han YH, Busler D, Hong Y, Tian Y, Chen C, and Rodrigues AD (2010) Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human liver drug transporters. Drug Metab Dispos 38:1072-1082.
57. Hartmann M, Huber R, Bliesath H, Steinijans VW, Koch HJ, Wurst W, and Kunz K (1995) Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Int J Clin Pharmacol Ther 33:481-485.
58. Hartmann M, Huber R, Bliesath H, Steinijans VW, Koch HJ, Wurst W, and Kunz K (1996) Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Int J Clin Pharmacol Ther 34 (1 Suppl):S67-S71.
59. He X, Mo L, Li ZY, Tan ZR, Chen Y, and Ouyang DS (2012) Effects of curcumin on the pharmacokinetics of talinolol in human with ABCB1 polymorphism. Xenobiotica 42: 1248-1254.
60. Hemauer SJ, Patrikeeva SL, Wang X, Abdelrahman DR, Hankins GD, Ahmed MS, and Nanovskaya TN (2010) Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. Biochem Pharmacol 80:1080-1086.
61. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, and Sugiyama Y (2005) Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68: 800-807.
62. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, and Kim RB (2006) Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130:1793-1806.
63. Hofman J, Kucera R, Cihalova D, Klimes J, Ceckova M, and Staud F (2013) Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1). PLoS One 8:e75520.
64. Huber R, Bliesath H, Hartmann M, Steinijans VW, Koch H, Mascher H, and Wurst W (1998) Pantoprazole does not interact with the pharmacokinetics of carbamazepine. Int J Clin Pharmacol Ther 36:521-524.
65. Hyafil F, Vergely C, Du Vignaud P, and Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53: 4595-4602.
66. Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, Fujino H, Hirano M, Kusuhara H, and Irie S, et al. (2007) SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 82:541-547.
67. Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, and Sugimoto Y (2003) Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol 64: 610-618.
68. Imai Y, Tsukahara S, Asada S, and Sugimoto Y (2004) Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 64:4346-4352.
69. Itagaki F, Homma M, Yuzawa K, Nishimura M, Naito S, Ueda N, Ohkohchi N, and Kohda Y (2004) Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. J Pharm Pharmacol 56:1055-1059.
70. Jada SR, Lim R, Wong CI, Shu X, Lee SC, Zhou Q, Goh BC, and Chowbay B (2007) Role of UGT1A1∗6, UGT1A1∗28 and ABCG2 c.421C.A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci 98:1461-1467.
71. Jamei M, Bajot F, Neuhoff S, Barter Z, Yang J, Rostami-Hodjegan A, and Rowland-Yeo K (2014) A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine. Clin Pharmacokinet 53:73-87.
72. Jani M, Makai I, Kis E, Szabó P, Nagy T, Krajcsi P, and Lespine A (2011) Ivermectin interacts with human ABCG2. J Pharm Sci 100:94-97.
73. Jani M, Szabó P, Kis E, Molnár E, Glavinas H, and Krajcsi P (2009) Kinetic characterization of sulfasalazine transport by human ATP-binding cassette G2. Biol Pharm Bull 32:497-499.
74. Jin HE, Song B, Kim SB, Shim WS, Kim DD, Chong S, Chung SJ, and Shim CK (2013) Transport of gemifloxacin, a 4th generation quinolone antibiotic, in the Caco-2 and engineered MDCKII cells, and potential involvement of efflux transporters in the intestinal absorption of the drug. Xenobiotica 43:355-367.
75. Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston JB, and Galetin A, et al. (2012) Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos 40:1007-1017.
76. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, and Schinkel AH (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92:1651-1656.
77. Juan H, Terhaag B, Cong Z, Bi-Kui Z, Rong-Hua Z, Feng W, Fen-Li S, Juan S, Jing T, and Wen-Xing P (2007) Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers. Eur J Clin Pharmacol 63:663-668.
78. Kalvass JC, Polli JW, Bourdet DL, Feng B, Huang SM, Liu X, Smith QR, Zhang LK, and Zamek-Gliszczynski MJ; International Transporter Consortium (2013) Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position. Clin Pharmacol Ther 94:80-94.
79. Karibe T, Hagihara-Nakagomi R, Abe K, Imaoka T, Mikkaichi T, Yasuda S, Hirouchi M, Watanabe N, Okudaira N, and Izumi T (2014) Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates. Pharm Res DOI:10.1007/s11095-014-1563-4 [published ahead of print].
80. Karlgren M, Ahlin G, Bergström CA, Svensson R, Palm J, and Artursson P (2012a) In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. Pharm Res 29:411-426.
81. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, and Artursson P (2012b) Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem 55:4740-4763.
82. Kawahara H, Noguchi K, Katayama K, Mitsuhashi J, and Sugimoto Y (2010) Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T.C) of BCRP/ABCG2 gene. Cancer Sci 101:1493-1500.
83. Kenny JR, Mukadam S, Zhang C, Tay S, Collins C, Galetin A, and Khojasteh SC (2012) Drugdrug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction. Pharm Res 29:1960-1976.
84. Keskitalo JE, Pasanen MK, Neuvonen PJ, and Niemi M (2009a) Different effects of the ABCG2 c.421C.A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 10:1617-1624.
85. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, and Niemi M (2009b) ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 86:197-203.
86. Kim HS, Sunwoo YE, Ryu JY, Kang HJ, Jung HE, Song IS, Kim EY, Shim JC, Shon JH, and Shin JG (2007) The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine. Br J Clin Pharmacol 64:645-654.
87. Kim MJ, Lee JW, Oh KS, Choi CS, Kim KH, Han WS, Yoon CN, Chung ES, Kim DH, and Shin JG (2013) The tyrosine kinase inhibitor nilotinib selectively inhibits CYP2C8 activities in human liver microsomes. Drug Metab Pharmacokinet 28:462-467.
88. Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, and Hoody DW (2008) Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr 47:570-578.
89. Kitamura S, Maeda K, Wang Y, and Sugiyama Y (2008) Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36:2014-2023.
90. Koch HJ, Hartmann M, Bliesath H, Huber R, Steinijans VW, Mascher H, and Wurst W (1996) Pantoprazole has no influence on steady state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers. Int J Clin Pharmacol Ther 34:420-423.
91. Kondo C, Suzuki H, Itoda M, Ozawa S, Sawada J, Kobayashi D, Ieiri I, Mine K, Ohtsubo K, and Sugiyama Y (2004) Functional analysis of SNPs variants of BCRP/ABCG2. Pharm Res 21:1895-1903.
92. Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, and Schellens JH (2002) Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20: 2943-2950.
93. Kuppens IE, Witteveen EO, Jewell RC, Radema SA, Paul EM, Mangum SG, Beijnen JH, Voest EE, and Schellens JH (2007) A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res 13: 3276-3285.
94. Kusuhara H, Furuie H, Inano A, Sunagawa A, Yamada S, Wu C, Fukizawa S, Morimoto N, Ieiri I, and Morishita M, et al. (2012) Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. Br J Pharmacol 166: 1793-1803.
95. Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, and Schinkel AH (2010) Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther 9:319-326.
96. Lainey E, Sébert M, Thépot S, Scoazec M, Bouteloup C, Leroy C, De Botton S, Galluzzi L, Fenaux P, and Kroemer G (2012) Erlotinib antagonizes ABC transporters in acute myeloid leukemia. Cell Cycle 11:4079-4092.
97. Lee HK, Hu M, Lui SS, Ho CS, Wong CK, and Tomlinson B (2013) Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics 14:1283-94.
98. Leggas M, Panetta JC, Zhuang Y, Schuetz JD, Johnston B, Bai F, Sorrentino B, Zhou S, Houghton PJ, and Stewart CF (2006) Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res 66:4802-4807.
99. Li H, Jin HE, Kim W, Han YH, Kim DD, Chung SJ, and Shim CK (2008) Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. Pharm Res 25:2601-2612.
100. Li J, Volpe DA, Wang Y, Zhang W, Bode C, Owen A, and Hidalgo IJ (2011a) Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos 39:1196-1202.
101. Li J, Wang Y, Zhang W, Huang Y, Hein K, and Hidalgo IJ (2012) The role of a basolateral transporter in rosuvastatin transport and its interplay with apical breast cancer resistance protein in polarized cell monolayer systems. Drug Metab Dispos 40:2102-2108.
102. Li L, Sham YY, Bikadi Z, and Elmquist WF (2011b) pH-Dependent transport of pemetrexed by breast cancer resistance protein. Drug Metab Dispos 39:1478-1485.
103. Li R, Bi YA, Lai Y, Sugano K, Steyn SJ, Trapa PE, and Di L (2014) Permeability comparison between hepatocyte and low efflux MDCKII cell monolayer. AAPS J 16:802-809.
104. Li X, Kamenecka TM, and Cameron MD (2010) Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile. Drug Metab Dispos 38:1238-1245.
105. Li XQ, Andersson TB, Ahlström M, and Weidolf L (2004) Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32:821-827.
106. Lin X, Skolnik S, Chen X, and Wang J (2011) Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. Drug Metab Dispos 39:265-274.
107. Liu Y, Ramírez J, House L, and Ratain MJ (2010) Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug Metab Dispos 38:32-39.
108. Lorf T, Ramadori G, Ringe B, and Schwörer H (2000) The effect of pantoprazole on tacrolimus and cyclosporin A blood concentration in transplant recipients. Eur J Clin Pharmacol 56: 439-440.
109. MacFarlane RJ and Gelmon KA (2011) Lapatinib for breast cancer: a review of the current literature. Expert Opin Drug Saf 10:109-121.
110. MacLean C, Moenning U, Reichel A, and Fricker G (2008) Closing the gaps: a full scan of the intestinal expression of p-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats. Drug Metab Dispos 36:1249-1254.
111. Macpherson IR, Poondru S, Simon GR, Gedrich R, Brock K, Hopkins CA, Stewart K, Stephens A, and Evans TR (2013) A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours. Eur J Cancer 49:782-789.
112. Malingré MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM, Ten Bokkel Huinink WW, and Schellens JH (2001) Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 84:42-47.
113. Mao Q and Unadkat JD (2005) Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 7:E118-E133.
114. Marchetti S, Pluim D, van Eijndhoven M, van Tellingen O, Mazzanti R, Beijnen JH, and Schellens JH (2013) Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA. Invest New Drugs 31:1125-1135.
115. Martin PD, Warwick MJ, Dane AL, Brindley C, and Short T (2003) Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 25:2553-2563.
116. Matsuo H, Takada T, Ichida K, Nakamura T, Nakayama A, Ikebuchi Y, Ito K, Kusanagi Y, Chiba T, Tadokoro S, et al. (2009) Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci Transl Med 1:5ra11.
117. Ménochet K, Kenworthy KE, Houston JB, and Galetin A (2012) Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes. Drug Metab Dispos 40:1744-1756.
118. Merino G, Alvarez AI, Pulido MM, Molina AJ, Schinkel AH, and Prieto JG (2006) Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos 34:690-695.
119. Merino G, Perez M, Real R, Egido E, Prieto JG, and Alvarez AI (2010) In vivo inhibition of BCRP/ABCG2 mediated transport of nitrofurantoin by the isoflavones genistein and daidzein: a comparative study in Bcrp1 (-/-) mice. Pharm Res 27:2098-2105.
120. Messersmith WA, Laheru DA, Senzer NN, Donehower RC, Grouleff P, Rogers T, Kelley SK, Ramies DA, Lum BL, and Hidalgo M (2004) Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res 10:6522-6527.
121. Middle MV, Müller FO, Schall R, Groenewoud G, Hundt HK, Huber R, Bliesath H, and Steinijans VW (1995) No influence of pantoprazole on the pharmacokinetics of phenytoin. Int J Clin Pharmacol Ther 33:304-307.
122. Middle MV, Müller FO, Schall R, Groenewoud G, Hundt HK, Huber R, Bliesath H, and Steinijans VW (1996) No influence of pantoprazole on the pharmacokinetics of phenytoin. Int J Clin Pharmacol Ther 34 (1 Suppl):S72-S75.
123. Midgley RS, Kerr DJ, Flaherty KT, Stevenson JP, Pratap SE, Koch KM, Smith DA, Versola M, Fleming RA, and Ward C, et al. (2007) A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Ann Oncol 18: 2025-2029.
124. Milton DT, Riely GJ, Azzoli CG, Gomez JE, Heelan RT, Kris MG, Krug LM, Pao W, Pizzo B, and Rizvi NA, et al. (2007) Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 110:599-605.
125. Minematsu T and Giacomini KM (2011) Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther 10: 531-539.
126. Mizuno N, Takahashi T, Kusuhara H, Schuetz JD, Niwa T, and Sugiyama Y (2007) Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistanceassociated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one). Drug Metab Dispos 35:2045-2052.
127. Molina JR, Kaufmann SH, Reid JM, Rubin SD, Gálvez-Peralta M, Friedman R, Flatten KS, Koch KM, Gilmer TM, and Mullin RJ, et al. (2008) Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. Clin Cancer Res 14:7900-7908.
128. Moody DE, Liu F, and Fang WB (2013) In vitro inhibition of methadone and oxycodone cytochrome P450-dependent metabolism: reversible inhibition by H2-receptor agonists and proton-pump inhibitors. J Anal Toxicol 37:476-485.
129. Nagasaka Y, Oda K, Iwatsubo T, Kawamura A, and Usui T (2012) Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier. Biopharm Drug Dispos 33:304-315.
130. Nakatomi K, Yoshikawa M, Oka M, Ikegami Y, Hayasaka S, Sano K, Shiozawa K, Kawabata S, Soda H, and Ishikawa T, et al. (2001) Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun 288:827-832.
131. Ni Z, Bikadi Z, Rosenberg MF, and Mao Q (2010) Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab 11:603-617.
132. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, and Sugimoto Y (2009) Substratedependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci 100:1701-1707.
133. Oberoi RK, Mittapalli RK, and Elmquist WF (2013) Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain. J Pharmacol Exp Ther 347:755-764.
134. Ohura K, Nozawa T, Murakami K, and Imai T (2011) Evaluation of transport mechanism of prodrugs and parent drugs formed by intracellular metabolism in Caco-2 cells with modified carboxylesterase activity: temocapril as a model case. J Pharm Sci 100:3985-3994.
135. Oostendorp RL, van-de-Steeg E, van-der-Kruijssen CM, Beijnen JH, Kenworthy KE, Schinkel AH, and Schellens JH (2009) Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metab Dispos 37:917-923.
136. Pan Y, Chothe PP, and Swaan PW (2013) Identification of novel breast cancer resistance protein (BCRP) inhibitors by virtual screening. Mol Pharm 10:1236-1248.
137. Pang KS (2003) Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metab Dispos 31:1507-1519.
138. Pasanen MK, Fredrikson H, Neuvonen PJ, and Niemi M (2007) Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82:726-733.
139. Pauli-Magnus C, Rekersbrink S, Klotz U, and Fromm MF (2001) Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 364:551-557.
140. Pavek P, Merino G, Wagenaar E, Bolscher E, Novotna M, Jonker JW, and Schinkel AH (2005) Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4, 5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther 312:144-152.
141. Pfeifer ND, Bridges AS, Ferslew BC, Hardwick RN, and Brouwer KL (2013a) Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver. J Pharmacol Exp Ther 347:737-745.
142. Pfeifer ND, Yang K, and Brouwer KL (2013b) Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes. J Pharmacol Exp Ther 347:727-736.
143. Pham PA, la Porte CJ, Lee LS, van Heeswijk R, Sabo JP, Elgadi MM, Piliero PJ, Barditch-Crovo P, Fuchs E, and Flexner C, et al. (2009) Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother 53:4385-4392.
144. Planting AS, Sonneveld P, van der Gaast A, Sparreboom A, van der Burg ME, Luyten GP, de Leeuw K, de Boer-Dennert M, Wissel PS, and Jewell RC, et al. (2005) A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemother Pharmacol 55:91-99.
145. Poirier A, Portmann R, Cascais AC, Bader U, Walter I, Ullah M, and Funk C (2014) The need for human breast cancer resistance protein substrate and inhibition evaluation in drug discovery and development: why, when, and how? Drug Metab Dispos 42:1466-1477.
146. Pollex EK, Anger G, Hutson J, Koren G, and Piquette-Miller M (2010) Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP singlenucleotide polymorphism. Drug Metab Dispos 38:740-744.
147. Polli JW, Humphreys JE, Harmon KA, Castellino S, O'Mara MJ, Olson KL, John-Williams LS, Koch KM, and Serabjit-Singh CJ (2008) The role of efflux and uptake transporters in [N-3- chloro-4-[(3-fluorobenzyl)oxy]phenyl-6-[5-([2-(methylsulfonyl)ethyl]aminomethyl)-2-furyl]- 4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 36:695-701.
148. Prueksaritanont T, Chu X, Evers R, Klopfer SO, Caro L, Kothare PA, Dempsey C, Rasmussen S, Houle R, and Chan G, et al. (2014) Pitavastatin is a more sensitive and selective organic aniontransporting polypeptide 1B clinical probe than rosuvastatin. Br J Clin Pharmacol 78:587-598.
149. Ranchon F, Vantard N, Gouraud A, Schwiertz V, Franchon E, Pham BN, Vial T, You B, Bouafia F, and Salles G, et al. (2011) Suspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibitors: a case report-should the practice be changed? Chemotherapy 57: 225-229.
150. Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, Webster LO, Harmon KA, Clarke JD, and Polli JW (2013) In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos 41:353-361.
151. Reginato AM, Mount DB, Yang I, and Choi HK (2012) The genetics of hyperuricaemia and gout. Nat Rev Rheumatol 8:610-621.
152. Remes-Troche JM, Sobrino-Cossío S, Soto-Pérez JC, Teramoto-Matsubara O, Morales-Arámbula M, Orozco-Gamiz A, Tamayo de la Cuesta JL, and Mateos G (2014) Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study. Clin Drug Investig 34:83-93.
153. Reyner EL, Sevidal S, West MA, Clouser-Roche A, Freiwald S, Fenner K, Ullah M, Lee CA, and Smith BJ (2013) In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions. Drug Metab Dispos 41:1575-1583.
154. Robert F, Sandler A, Schiller JH, Liu G, Harper K, Verkh L, Huang X, Ilagan J, Tye L, and Chao R, et al. (2010) Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Cancer Chemother Pharmacol 66:669-680.
155. Robey RW, Ierano C, Zhan Z, and Bates SE (2011) The challenge of exploiting ABCG2 in the clinic. Curr Pharm Biotechnol 12:595-608.
156. Saison C, Helias V, Ballif BA, Peyrard T, Puy H, Miyazaki T, Perrot S, Vayssier-Taussat M, Waldner M, and Le Pennec PY, et al. (2012) Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior. Nat Genet 44:174-177.
157. Saito H, Hirano H, Nakagawa H, Fukami T, Oosumi K, Murakami K, Kimura H, Kouchi T, Konomi M, and Tao E, et al. (2006) A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions. J Pharmacol Exp Ther 317:1114-1124.
158. Sharma RA, Gescher AJ, and Steward WP (2005) Curcumin: the story so far. Eur J Cancer 41: 1955-1968.
159. Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, and Sugiyama Y (2013) Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos 34:45-78.
160. Shukla S, Kouanda A, Silverton L, Talele TT, and Ambudkar SV (2014) Pharmacophore modeling of nilotinib as an inhibitor of ATP-binding cassette drug transporters and BCR-ABL kinase using a three-dimensional quantitative structure-activity relationship approach. Mol Pharm 11:2313-2322.
161. Shukla S, Zaher H, Hartz A, Bauer B, Ware JA, and Ambudkar SV (2009) Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res 26:480-487.
162. Si M, Zhao J, Li X, Tian JG, Li YG, and Li JM (2013) Reversion effects of curcumin on multidrug resistance of MNNG/HOS human osteosarcoma cells in vitro and in vivo through regulation of P-glycoprotein. Chin Med J (Engl) 126:4116-4123.
163. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, and Schneck DW (2004) Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76:167-177.
164. Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves C, Verweij J, and McLeod HL (2004) Diflomotecan pharmacokinetics in relation to ABCG2 421C.A genotype. Clin Pharmacol Ther 76:38-44.
165. Sparreboom A, Loos WJ, Burger H, Sissung TM, Verweij J, Figg WD, Nooter K, and Gelderblom H (2005) Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol Ther 4:650-658.
166. Stewart CF, Tagen M, Schwartzberg LS, Blakely LJ, Tauer KW, and Smiley LM (2014) Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors. Cancer Chemother Pharmacol 73:561-568.
167. Sugimoto H, Matsumoto S, Tachibana M, Niwa S, Hirabayashi H, Amano N, and Moriwaki T (2011) Establishment of in vitro P-glycoprotein inhibition assay and its exclusion criteria to assess the risk of drug-drug interaction at the drug discovery stage. J Pharm Sci 100: 4013-4023.
168. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, and Kohda Y (2009) Coadministration of proton pump inhibitors delays elimination of plasma methotrexate in highdose methotrexate therapy. Br J Clin Pharmacol 67:44-49.
169. Swaisland HC, Ranson M, Smith RP, Leadbetter J, Laight A, McKillop D, and Wild MJ (2005) Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 44:1067-1081.
170. Tamaki H, Satoh H, Hori S, Ohtani H, and Sawada Y (2010) Inhibitory effects of herbal extracts on breast cancer resistance protein (BCRP) and structure-inhibitory potency relationship of isoflavonoids. Drug Metab Pharmacokinet 25:170-179.
171. Tamura A, Watanabe M, Saito H, Nakagawa H, Kamachi T, Okura I, and Ishikawa T (2006) Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport. Mol Pharmacol 70:287-296.
172. Tanaka M, Kamada I, Takahashi J, Kimura K, Matsukura H, and Tani Y (2014) Defining the Jr(a-) phenotype in the Japanese population. Transfusion 54:412-417.
173. Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, and Schinkel AH (2012a) Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer 130:223-233.
174. Tang SC, Lankheet NA, Poller B, Wagenaar E, Beijnen JH, and Schinkel AH (2012b) P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib. J Pharmacol Exp Ther 341: 164-173.
175. Thomas KS, Billingsley A, Amarshi N, and Nair BA (2010) Elevated international normalized ratio associated with concomitant warfarin and erlotinib. Am J Health Syst Pharm 67: 1426-1429.
176. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, and Chen ZS (2009) Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol 78:153-161.
177. Tomaru A, Morimoto N, Morishita M, Takayama K, Fujita T, Maeda K, Kusuhara H, and Sugiyama Y (2013) Studies on the intestinal absorption characteristics of sulfasalazine, a breast cancer resistance protein (BCRP) substrate. Drug Metab Pharmacokinet 28:71-74.
178. Tran HT, Zinner RG, Blumenschein GR Jr, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, and Herbst RS (2011) Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced non-small cell lung cancer (NSCLC). Invest New Drugs 29:499-505.
179. Tsamandouras N, Dickinson G, Guo Y, Hall S, Rostami-Hodjegan A, Galetin A, and Aarons L (2014) Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach. Clin Pharmacol Ther 96:90-100.
180. Urquhart BL, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI, Zaher H, Palandra J, Gregor JC, and Dresser GK, et al. (2008) Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet Genomics 18:439-448.
181. US Food and Drug Administration (2012) Guidance for Industry: Drug Interaction Studies- Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf.
182. van de Steeg E, Greupink R, Schreurs M, Nooijen IH, Verhoeckx KC, Hanemaaijer R, Ripken D, Monshouwer M, Vlaming ML, and DeGroot J, et al. (2013) Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1. Drug Metab Dispos 41:592-601.
183. Varma MV, Scialis RJ, Lin J, Bi YA, Rotter CJ, Goosen TC, and Yang X (2014) Mechanismbased pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide. AAPS J 16:736-748.
184. Veeraputhiran M and Sundermeyer M (2008) Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin. Clin Lung Cancer 9:232-234.
185. Volk EL and Schneider E (2003) Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 63:5538-5543.
186. Wang L, Leggas M, Empey PE, and McNamara PJ (2012) Stereoselective interaction of pantoprazole with ABCG2. II. In vitro flux analysis. Drug Metab Dispos 40:1024-1031.
187. Wang Q, Strab R, Kardos P, Ferguson C, Li J, Owen A, and Hidalgo IJ (2008) Application and limitation of inhibitors in drug-transporter interactions studies. Int J Pharm 356:12-18.
188. Wang Y, Wang M, Qi H, Pan P, Hou T, Li J, He G, and Zhang H (2014) Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug-drug interaction potentials. Drug Metab Dispos 42:782-795.
189. Ware JA, Dalziel G, Jin JY, Pellett JD, Smelick GS, West DA, Salphati L, Ding X, Sutton R, and Fridyland J, et al. (2013) Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility. Mol Pharm 10:4074-4081.
190. Watanabe T, Kusuhara H, Maeda K, Shitara Y, and Sugiyama Y (2009) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652-662.
191. Wei Y, Wu B, Jiang W, Yin T, Jia X, Basu S, Yang G, and Hu M (2013) Revolving door action of breast cancer resistance protein (BCRP) facilitates or controls the efflux of flavone glucuronides from UGT1A9-overexpressing HeLa cells. Mol Pharm 10:1736-1750.
192. Weiss J and Haefeli WE (2013) Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int J Antimicrob Agents 41:484-487.
193. Wilding G, Soulie P, Trump D, Das-Gupta A, and Small E (2006) Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. Cancer 106:1917-1924.
194. Wright JA, Haslam IS, Coleman T, and Simmons NL (2011) Breast cancer resistance protein BCRP (ABCG2)-mediated transepithelial nitrofurantoin secretion and its regulation in human intestinal epithelial (Caco-2) layers. Eur J Pharmacol 672:70-76.
195. Xia CQ, Liu N, Miwa GT, and Gan LS (2007) Interactions of cyclosporin a with breast cancer resistance protein. Drug Metab Dispos 35:576-582.
196. Xiao G, Black C, Hetu G, Sands E, Wang J, Caputo R, Rohde E, and Gan LS (2012) Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates. Drug Metab Dispos 40:779-787.
197. Xiao Y, Davidson R, Smith A, Pereira D, Zhao S, Soglia J, Gebhard D, de-Morais S, and Duignan DB (2006) A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line. Mol Pharm 3:45-54.
198. Yamamoto N, Horiike A, Fujisaka Y, Murakami H, Shimoyama T, Yamada Y, and Tamura T (2008) Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factorreceptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 61:489-496.
199. Yamasaki Y, Ieiri I, Kusuhara H, Sasaki T, Kimura M, Tabuchi H, Ando Y, Irie S, Ware J, and Nakai Y, et al. (2008) Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin Pharmacol Ther 84:95-103.
200. Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y, and Sugimoto Y (2004) Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 3:1119-1125.
201. Yang JJ, Milton MN, Yu S, Liao M, Liu N, Wu JT, Gan L, Balani SK, Lee FW, and Prakash S, et al. (2010) P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Drug Metab Lett 4:201-212.
202. Ye L, Yang X, Yang Z, Gao S, Yin T, Liu W, Wang F, Hu M, and Liu Z (2013) The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells. Toxicol Lett 216:86-99.
203. Yin OQ, Gallagher N, Fischer D, Zhao L, Zhou W, Leroy E, Golor G, and Schran H (2011) Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects. Clin Drug Investig 31:169-179.
204. Yoshida N, Takada T, Yamamura Y, Adachi I, Suzuki H, and Kawakami J (2008) Inhibitory effects of terpenoids on multidrug resistance-associated protein 2- and breast cancer resistance protein-mediated transport. Drug Metab Dispos 36:1206-1211.
205. Zaher H, Khan AA, Palandra J, Brayman TG, Yu L, and Ware JA (2006) Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol Pharm 3:55-61.
206. Zamek-Gliszczynski MJ, Bedwell DW, Bao JQ, and Higgins JW (2012) Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics. Drug Metab Dispos 40:1825-1833.
207. Zelinski T, Coghlan G, Liu XQ, and Reid ME (2012) ABCG2 null alleles define the Jr(a-) blood group phenotype. Nat Genet 44:131-132.
208. Zhang D, He K, Herbst JJ, Kolb J, Shou W, Wang L, Balimane PV, Han YH, Gan J, and Frost CE, et al. (2013) Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos 41:827-835.
209. Zhang D, Zhu M, and Humphreys WG (2008) Drug Metabolism in Drug Design and Development: Basic Concepts and Practice, Wiley-Interscience, Hoboken, NJ.
210. Zhang S, Wang X, Sagawa K, and Morris ME (2005a) Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice. Drug Metab Dispos 33:341-348.
211. Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, and Fen Jiang, et al. (2006) Role of BCRP 421C.A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 373:99-103.
212. Zhang Y, Gupta A, Wang H, Zhou L, Vethanayagam RR, Unadkat JD, and Mao Q (2005b) BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm Res 22: 2023-2034.
213. Zhou L, Schmidt K, Nelson FR, Zelesky V, Troutman MD, and Feng B (2009) The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl) ethoxy)phenyl)propanoic acid (PF-407288) in mice. Drug Metab Dispos 37:946-955.
214. Zhou Q, Chen QX, Ruan ZR, Yuan H, Xu HM, and Zeng S (2013) CYP2C9∗3(1075A. C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics. Pharmazie 68:187-194.
215. Zouboulis-Vafiadis I, Paraskevas E, Tzourmakliotis D, Hatzikyriakou M, Mestoussi A, Vasdekis V, Katsilabros N, Arhimandritis A, and Papadokostopoulou A (2014) An open-label, noncomparative, non-interventional, multi-center, post-authorization safety study on the administration of rabeprazole to adults with gastro-esophageal reflux disease. Ann Gastroenterol 27: 133-138.
216. Zvyaga T, Chang SY, Chen C, Yang Z, Vuppugalla R, Hurley J, Thorndike D, Wagner A, Chimalakonda A, and Rodrigues AD (2012) Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos 40:1698-1711.